Ceribell, Inc. (CBLL)

In the past six months, Ceribell's stock has experienced significant upward movement, with a recent decline. Key events impacting the stock include Q4 2025 financial results, FDA Breakthrough Status for AI-Based LVO Stroke Detection, insider selling, a CMS proposal for a new technology add-on payment, and analyst ratings. Ceribell reported Q4 2025 revenue of $24.8 million, a 34% increase year-over-year, and projected full-year 2026 revenue between $111 million and $115 million. Ceribell received FDA Breakthrough Status for its AI-based large vessel occlusion (LVO) stroke detection technology and FDA designation for an in-hospital LVO stroke detection device. There have been instances of insider selling. The Centers for Medicare & Medicaid Services (CMS) proposed a new technology add-on payment of up to $2,171 for Ceribell's delirium monitoring system. As of April 21, 2026, Ceribell has a consensus rating of "Moderate Buy" from six analysts, with an average 12-month price target of $23.20.

There is no explicit information available indicating specific demand seasonality for Ceribell, Inc.'s products and services. The company's growth outlook is promising, with anticipated revenue increases driven by rising demand for effective neurological diagnostics. The company's revenue has shown consistent growth, with a 36.09% increase in 2025 compared to the previous year, and projected annual growth of approximately 25% to 29% for 2026.

Ceribell, Inc. is a medical technology company focused on improving the diagnosis and management of patients with severe neurological conditions. It operates in the Healthcare sector, specifically in the Medical Devices industry, with a focus on neurological diagnostics. Ceribell's core offering is the Ceribell System, a point-of-care electroencephalography (EEG) platform designed for acute care settings. The system integrates portable hardware with AI-powered algorithms to enable quick diagnosis and continuous monitoring of patients at risk for seizures. Major products include Point-of-Care EEG, Clarity (an AI algorithm), and an EEG Portal.

Ceribell, Inc. is headquartered in Sunnyvale, California, United States. The company has a global presence through direct sales and distribution partnerships across North America, Europe, and select international markets. As of Q2 2025, over 550 U.S. hospitals were utilizing Ceribell systems. The company also recently achieved FedRAMP High authorization, which could expand its reach into federal healthcare systems.

Ceribell's brand reputation is largely tied to its innovative AI-based point-of-care EEG technology and its mission to improve neurological diagnostics in acute care settings. The company is seen as a leader in the medical devices industry, particularly in neurological diagnostics. A study published in May 2025 found that the Clarity algorithm did not detect seizures in four out of 21 patients experiencing them in a medical intensive care unit after cardiac arrest. Despite this, the company has received positive news regarding FDA approvals and designations for its devices, which generally bolsters its reputation.

Ceribell, Inc. has significant institutional ownership, with 118 institutional owners and shareholders holding a total of 28,337,620 shares. Institutions hold approximately 77.96% of the shares, while individuals hold about 10.09%. Major institutional and individual owners include TPG GP A, Llc, FMR Llc, Red Tree Management, LLC, BlackRock, Inc., Vanguard Group Inc, Bank of New York Mellon Corp, KCM Capital Inc, TimesSquare Capital Management, LLC, Federated Hermes, Inc., Geode Capital Management, Llc, Josef Parvizi, Juliet Tammenoms Bakker, and Xingjuan Chao.